SCD1 Antibody [H13N22]

Catalog No.: F3395

    Home Primary Antibodies SCD1 Antibody [H13N22]

    For research use only.

    Application: Reactivity:

    Usage Information

    Dilution
    1:1000
    1:30
    1:2000
    1:100
    1:500
    Application
    WB, IP, IHC, IF, FCM
    Reactivity
    Mouse, Rat, Human
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    42 kDa 50 kDa, 37 kDa, 28 kDa (cleavage product)
    *Why do the predicted and actual molecular weights differ?
    The following reasons may explain differences between the predicted and actual protein molecular weight.

    Datasheet & SDS

    Biological Description

    Specificity
    SCD1 Antibody [H13N22] detects endogenous levels of total SCD1 protein.
    Clone
    H13N22
    Synonym(s)
    FADS5; SCD1; SCDOS; SCD; Stearoyl-CoA desaturase; hSCD1; Acyl-CoA desaturase; Delta(9)-desaturase; Fatty acid desaturase; Delta-9 desaturase
    Background
    Stearoyl-CoA desaturase-1 (SCD1) is a membrane-bound enzyme predominantly localized in the endoplasmic reticulum. SCD1 is a key member of the lipid metabolism enzyme family, catalyzing the biosynthesis of monounsaturated fatty acids (MUFAs) from saturated fatty acyl-CoAs by introducing a cis double bond at the Δ9 position between the ninth and tenth carbon atoms. It is composed of four transmembrane domains that form a characteristic “mushroom-shaped” fold, with eight histidine residues at the catalytic site coordinating a diiron center crucial for enzymatic function. SCD1 converts stearoyl-CoA and palmitoyl-CoA into oleoyl-CoA and palmitoleoyl-CoA, respectively. These MUFAs are major constituents of membrane phospholipids, triglycerides, and cholesterol esters, thus regulating membrane fluidity and lipid signaling. SCD1 is central to fatty acid metabolism, energy homeostasis, and lipid biosynthesis, interacting with enzymes such as acetyl-CoA carboxylase and fatty acid synthase to maintain lipid balance. SCD1 modulates insulin sensitivity, as knockout models exhibit improved insulin signaling and resistance to obesity and hepatic steatosis, emphasizing its importance in metabolic syndrome and related diseases. SCD1 is also implicated in cancer progression by supporting the lipid metabolism required for tumor growth, making it a promising therapeutic target. Its activity depends on an electron transfer chain from NAD(P)H through cytochrome b5 reductase and cytochrome b5 to the diiron center, ensuring accurate double bond formation and substrate specificity.
    References
    • https://pubmed.ncbi.nlm.nih.gov/19066317/
    • https://pubmed.ncbi.nlm.nih.gov/32470559/

    Tech Support

    Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3
    If you have any other enquiries, please leave a message.

    * Indicates a Required Field

    Please enter your name.
    Please enter your email. Please enter a valid email address.
    Please write something to us.